The melanocortin-1 receptor (MC1R) is a seven-transmembrane (TM) G-protein-coupled receptor whose natural ligands are the melanocortin peptides, adrenocorticotropic hormone, and ␣-, ␤-, and ␥-melanocyte stimulating hormone (MSH). To test a previously constructed three-dimensional model of the molecular interaction between the long-acting, superpotent , and simultaneous mutation of multiple TM4, -5, and -6 tyrosine and phenylalanine residues suggests that aromatic-aromatic ligand-receptor interactions also participate in binding these melanocortins to the MC1R. These experiments appear to have identified some of the critical receptor residues involved in the ligand-receptor interactions between these melanocortins and the hMC1R.
]NH 2 (MT-II). Mutagenesis of acidic receptor residues Glu
94 in TM2 and Asp 117 or Asp 121 in TM3 significantly altered the binding affinity and potency of all four agonists suggesting that these receptor residues are important to the ligand-receptor interactions of all. A disproportionate change in agonist potency versus affinity observed with simultaneous mutation of these acidic residues (mutant constructs D117A/D121A or E94A/D117A/D121A) or introduction of a single positive charge (mutant construct D121K) also implicates these residues in receptor activation. In addition, results from the individual mutation of aromatic receptor residues Phe 175 , Phe 196 , and Phe 257 , and simultaneous mutation of multiple TM4, -5, and -6 tyrosine and phenylalanine residues suggests that aromatic-aromatic ligand-receptor interactions also participate in binding these melanocortins to the MC1R. These experiments appear to have identified some of the critical receptor residues involved in the ligand-receptor interactions between these melanocortins and the hMC1R.
The term melanocortin refers to several of the post-translational products of the pro-opiomelanocortin gene, adrenocorticotropic hormone (ACTH), 1 and ␣-, ␤-, and ␥-MSH. Besides the well known effects of these peptides on adrenal cortical steroidogenesis (ACTH) and pigmentation (␣-MSH and ACTH), melanocortins have also been implicated in a myriad of physiological processes including learning and memory, blood pressure control, immune modulation, and weight homeostasis among others (1-3).
All melanocortin peptides contain a core or "message" HisPhe-Arg-Trp sequence and, with the exception of ␥-MSH, also share a common heptapeptide sequence Met-Glu-His-Phe-ArgTrp-Gly (Fig. 1) . Two superpotent ␣-MSH analogs have been developed by altering the chirality of the phenylalanine in the core sequence and replacing methionine with norleucine, [ (4, 5) . Both NDP-MSH and MT-II have extremely prolonged activity (days) as compared with ␣-MSH (hours) in the classical frog and lizard skin darkening bioassays (4, 5) . There is some evidence to suggest that the basis for this residual activity lies, at least in part, on the slow dissociation rates of these ␣-MSH analogs (6) . This unique property of prolonged activity makes an understanding of the molecular interactions of these two compounds with its target receptors of particular interest.
To date five melanocortin receptor subtypes with different patterns of tissue expression in the central nervous system and peripheral body have been cloned. Designated melanocortin receptor (MCR) 1-5 for the order in which they were isolated, all five receptor subtypes belong to the family of seven transmembrane G-protein-coupled receptors and upon stimulation all subtypes activate adenylate cyclase and elevate intracellular 3Ј,5Ј-adenosine monophosphate. A unified nomenclature has been set forth in which the melanocyte melanocortin receptor, previously referred to as the ␣-MSH receptor, has been designated the melanocortin-1 receptor (MC1R). This newer terminology was adopted since studies with the cloned melanocortin receptor subtypes have demonstrated that with the exception of the melanocortin-2 receptor (the adrenocortical ACTH receptor) which is only activated by ACTH, all other subtypes are promiscuous in their activation by the melanocortins.
Each of the five MCR subtypes has its own signature profile of melanocortin activation. The human MC1R (hMC1R) is activated equally well by both ACTH and ␣-MSH while ␤-MSH is approximately half a log less potent and ␥-MSH is least potent. Interestingly, this is not the case with the rodent MC1R where ␣-MSH is more potent than ACTH (7) .
The molecular basis for the interaction of the melanocortins and their synthetic analogs with the hMC1R remains to be fully elucidated. Recently we published a three-dimensional molecular model of NDP-MSH complexing with hMC1R (8) .
The key pharmacological data used in developing this model are the following. Of paramount importance was the demon-stration that the tripeptide D-Phe 7 -Arg 8 -Trp 9 is the minimal active fragment of NDP-MSH that retains biological activity in the frog and lizard skin bioassays (9) . 2 Other studies established that bulky groups attached to either amino or carboxyl terminus of NDP-MSH did not significantly affect skin darkening (9) . This absence of interference was interpreted to mean that the ends of the molecule do not participate in the ligandreceptor interaction and probably face the extracellular environment. Yet other studies suggested that NDP-MSH forms a reverse-turn in the region of His (11, 12) . These pharmacological data were used to dock the NDP-MSH molecule inside hMC1R a distance of 8 -15 Å from the extracellular surface, a position felt to be appropriate for a peptide of its size. The model of hMC1R was built upon the scaffold of the archetypal TM7 structure of bacteriorhodopsin (13) , and modified to account for the G-protein-coupled receptor rhodopsin (14) , the presently accepted homology modeling technique for this class of receptors. Receptor residues that were able to interact with the positively charged hydrophilic Arg 8 and the aromatic hydrophobic D-Phe 7 and Trp 9 of NDP-MSH were then identified.
The previous three-dimensional model hypothesized that a series of amino acids in TM2, -3, and -7 form a hydrophilic binding pocket for the positively charged Arg 8 of NDP-MSH (8). Specific amino acids proposed to constitute this predominantly ionic binding pocket included acidic residues Glu 94 in TM2, Asp 117 and Asp 121 in TM3, and non-acidic residues Phe 280 and Asn 281 in TM7. The other major ligand-receptor interaction between NDP-MSH and hMC1R proposed in our previous three-dimensional model involved hydrophobic (aromatic-aromatic) interactions between the D-Phe 7 and Trp 9 residues of NDP-MSH and a series of phenylalanine 179, 195, 196, 257, 258 , and 280) and tyrosine (Tyr 182 and Tyr 183 ) residues in TM4, -5, and -6 of the receptor. These aromatic receptor residues were proposed to collectively constitute a hydrophobic ligand binding pocket. These studies were undertaken to test our previously constructed model of the molecular interactions between NDP-MSH and hMC1R using site-directed receptor mutagenesis to alter each of the residues identified by the model and observe the effects of these mutations on agonist binding affinity and potency.
EXPERIMENTAL PROCEDURES

Site-directed Mutagenesis-
The open reading frame of the hMC1R beginning at the start codon and ending slightly distal to the stop codon was subcloned into the BamHI site of M13 mp18 in the correct orientation for single stranded site-directed mutagenesis using the MutaGene T4 in vitro mutagenesis kit (Bio-Rad). Mutagenic oligonucleotides were synthesized on a Applied Biosystems 380B DNA synthesizer and after purification phosphorylated using T4 kinase. Alanine which has been widely used in receptor mutagenesis research because its small nonpolar side chain should only minimally alter receptor tertiary structure was the substitution chosen for the majority of these experiments. The presence of desired mutations was confirmed by single strand sequencing using Sequenase Version 2.0 (Life Science Products, Cleveland, OH). The mutant receptors were then excised from M13 using the restriction enzymes EcoRI and SalI and subcloned into the eukaryotic expression vector pBK-CMV (Stratagene, La Jolla, CA). Large scale plasmid preparations were performed after amplifying the receptor containing plasmids in Escherichia coli strain XL1-Blue (Stratagene) using an alkaline lysis method followed by purification of closed circular DNA over a CsCl gradient (15) .
Cell Transfection and Culture-For these studies HEK 293 cells were transfected with receptor plasmid DNA using 20 l of LipofectAmine Reagent (Life Technologies, Gaithersburg, MD) according to the manufacturers instructions. 5 g of mutant receptor plasmid DNA was routinely used to transfect the cells. After 24 h the cells were trypsinized and aliquoted onto 12-well plates (0.5 million cells/well) and grown in Dulbecco's modified Eagle's medium (Life Technologies) containing 4.5 g/100 ml glucose, 10% fetal calf serum, 1 mM sodium pyruvate. Cells were allowed to grow to confluence over the next 24 h before performing assays.
Ligand Binding-Iodinated NDP-MSH which is presently considered the radioligand of choice for MCR study (with the exception of MC2R which it does not bind) was used to assess agonist binding affinity. 125 Maintenance media was removed and the cells were washed twice with 0.5 ml of minimal essential medium (Life Technologies) containing 0.2% bovine serum albumin. Cold ligand was added immediately prior to addition of 3 ϫ 10 5 cpm of radioligand with a specific activity of 2,000 Ci/mmol and cells were incubated for 1 h at 37°C. Binding reactions were terminated by removing the media and washing the cells twice with minimal essential medium containing 0.2% bovine serum albumin. The cells were lysed with 1% Triton X-100 and 0.1 N NaOH. Radioactivity in the lysate was quantified in a Model 1285 Tracor Analytic ␥-counter. Nonspecific binding was determined by measuring the amount of 125 I-labeled NDP-MSH remaining bound in the presence of 10 Ϫ6 M unlabeled melanocortin and specific binding was calculated by subtracting nonspecifically bound radioactivity from total bound radioactivity. IC 50 values reported in Table I are mean Ϯ S.E. To quantify receptor expression competitive binding assays were performed to determine the amount of receptor protein according to the equation
cAMP Measurement-For this assay maintenance media was removed and cells were washed twice with Earle's balanced salt solution (Life Technologies) containing 10 mM HEPES (pH 7.4), 1 mM glutamine, 26.5 mM sodium bicarbonate, and 1 mg/ml bovine serum albumin. Cells were incubated for 1 h at 37°C with melanocortin agonist in Earle's balanced salt solution containing 10 Ϫ4 M isobutylmethylxanthine. The reaction was stopped by adding ice-cold 100% ethanol (500 l/well). Cells in each well were scraped and transferred to a 1.5-ml tube and centrifuged for 10 min at 1900 ϫ g. The supernatant was evaporated in a 55°C water bath with prepurified nitrogen gas. cAMP content was measured using a competitive binding assay kit (TRK 432, Amersham) according to instructions. Each experiment was performed a minimum of three times with duplicate wells. The mean value of the data were fit to a sigmoid curve with a variable slope factor using the non-linear squares regression in GraphPad Prism. EC 50 values reported in Table  II are mean Ϯ S.E. A Student's t test was used to determine the statistical significance of changes in affinity and potency (p Ͻ 0.05 was considered significant).
FIG. 1.
The amino acid sequence of the naturally occurring and synthetic melanocortin peptides used in this study.
RESULTS
Fig
. 2 schematically shows the hMC1R residues mutated in these experiments in standard two-dimensional form.
Characterization of the Wild-type hMC1R- Fig. 3 (left panel) shows the binding affinity of the melanocortin agonists used in these studies for the wild-type hMC1R (IC 50 values for the wild-type hMC1R and mutant receptors are in Table I ). The affinity of MT-II Ͼ NDP-MSH Ͼ ␣-MSH Ͼ ␥-MSH. Fig. 3 (right panel) shows the receptor-mediated cAMP response of the melanocortin agonists at the wild-type hMC1R (EC 50 values for the wild-type hMC1R and mutant receptors are in Table II ). All four agonists are fully efficacious. Both synthetic analogs have greater affinity and potency than the naturally occurring peptides. MT-II is slightly more potent than NDP-MSH which is consistent with the binding studies and with previous studies by ourselves and others (5, 17) . Both the IC 50 and EC 50 values for all four agonists closely parallel each other.
From a theoretical standpoint binding studies should not be effected by the level of mutant receptor expression. However, one of our major experimental concerns was that the ability of mutant receptors to generate cAMP might be affected by the level of receptor expression. Low mutant receptor expression and resultant under utilization of the cAMP generating machinery of the HEK 293 cell compared with the wild-type receptor might cause apparent rightward shifts of agonist potency at mutant receptors. This would result in improperly attributing shifts in EC 50 to the effects of a mutation. We addressed this concern by examining two aspects of hMC1R expression in HEK 293 cells. First, we examined the effect that transfection of varying amounts of wild-type hMC1R plasmid DNA had on the binding affinity and potency of NDP-MSH. As shown in Fig. 4 (left panel) , the binding affinity of NDP-MSH was unaffected by the amount of hMC1R plasmid transfected over a wide range of DNA (0.25 to 5 g). Fig. 4 (right panel) shows the effect of transfecting the same amounts of wild-type hMC1R plasmid DNA on the potency of the NDP-MSH-stimulated cAMP response. Although the E max varied with the DNA dose the potency of cAMP generation was unaffected except at the 0.25 g of dose where it was shifted rightward half a log (EC 50 Ϯ S.E. of NDP-MSH with the various DNA amounts used for transfection were: 5 g ϭ 0.24 Ϯ 0.06 nM; 1 g ϭ 0.25 Ϯ 0.03 nM; 0.5 g ϭ 0.25 Ϯ 0.04 nM; 0.25 g ϭ 0.67 Ϯ 0.07 nM). Second, we used competitive binding assays to calculate the B max of the mutant receptors expressed in HEK 293 cells (Table I) . As one would expect, the level of wild-type hMC1R expression increased with transfection of greater amounts of plasmid DNA. The relationship of the B max to the amount of receptor plasmid DNA transfected into the HEK 293 cells was as follows: 0.25 g of wild-type DNA f 55 fmol/mg; 0.5 g f 89 fmol/mg; 1 g f 201 fmol/mg; 5 g f 369 fmol/mg. These experiments allowed us to correlate the amount of wild-type hMC1R plasmid DNA which led to the decrease in NDP-MSH potency (0.25 g) with a B max of 55 fmol/mg. Notably, in all instances, the B max of mutant receptors exceeded the 55 fmol/mg level by at least 2-fold.
Mutations in the Predominantly Ionic Receptor Binding Pocket-Mutation of Glu
94 to alanine had a very significant effect on both the binding affinity and potency of ␣-MSH and MT-II and almost completely abolished the ability of ␥-MSH to interact with the receptor (Fig. 5) . In contrast to the other agonists, this mutation caused only a comparatively small change in the binding affinity and potency of NDP-MSH (Ͻ half a log versus Ͼ one log for the other agonists). Mutation of the negatively charged TM3 residues Asp 117 or Asp 121 to alanine also had very profound effects on the binding affinity and potency of ␣-MSH, MT-II, and ␥-MSH (Fig. 5) . Unlike the E94A mutation, these TM3 mutations produced more significant effects on NDP-MSH binding affinity and potency. With all three mutations (E94A, D117A, and D121A) the changes in agonist IC 50 and EC 50 values closely paralleled each other.
To further examine the concept proposed by our model that acidic hMC1R residues Glu 94 , Asp 117 , and Asp 121 interact with a single ligand amino acid Arg 8 of NDP-MSH we examined the effects of more complex mutations of those receptor residues. Alanine substitution of two (mutant D117A/D121A) and three (mutant E94A/D117A/D121A) of these acidic residues produced 50 , p Ͻ 0.05) and a somewhat greater loss in that parameter for the other agonists (2-7-fold). All agonists displayed a loss of potency that was proportionate to their loss of binding affinity. Since a receptor is a flexible "breathing" molecule, Phe 258 was also proposed as a receptor residue with the potential to interact with D-Phe 7 of NDP-MSH. Simultaneous substitution of these adjacent phenylalanines (mutation F257A/F258A) slightly augmented the loss in agonist binding affinity and potency observed with the single F257A mutation (Fig. 7) .
The concept of an aromatic network put forth in our model was further examined with simultaneous mutation of two or more aromatic residues. We based these more complex mutations on receptor residue Phe 196 since this residue (according to our model) has the potential to interact with both D-Phe 7 and Trp 9 of NDP-MSH. The double mutants F179A/F196A and Y182A/F196A both demonstrated small but consistent losses of binding affinity as compared with F196A alone. Encouraged by this finding, we extended this rationale still further and created mutant receptors with even greater numbers of aromatic mutations. In general, the triple aromatic mutation (F175A/ Y182A/F196A) and quadruple aromatic mutation (F175A/ F179A/Y182A/F196A) caused small but consistent losses in agonist binding affinity beyond those observed with the double mutants (Fig. 7) . All complex aromatic mutations had their greatest effect on ␥-MSH.
Other Mutation-Alanine substitution of His 260 in TM6, a receptor residue which is conserved in all MCR subtypes, differentially affected the binding affinity of the naturally occurring agonists and the synthetic ␣-MSH analogs. Mutation H260A caused a one log decrease in binding affinity and potency of ␣-MSH and ␥-MSH but, had no significant effect on the affinity or potency of either NDP-MSH or MT-II. the human melanocortin-1 receptor (hMC1R). In addition to examining the effects of site-directed receptor mutagenesis on NDP-MSH, we also examined the effects of these same mutations on the related peptides ␣-and ␥-MSH and MT-II. It is important to emphasize that while the ligand-receptor interactions of NDP-MSH and hMC1R might be expected to have some relevance to the ligand-receptor interactions of ␣-MSH, ␥-MSH, and MT-II with hMC1R (since the sequences of all contain many common amino acids) differences might also exist. In fact, we have modeled the receptor interaction of Trp 9 in the sequence of MT-II somewhat differently from that of NDP-MSH (8) . Measurement of cAMP generation allowed us to compare changes in agonist potency with changes in agonist binding affinity and, therefore, gain some insight into the process of receptor activation. Important to this latter measurement, examination of our experimental system demonstrated that the level of mutant receptor expression achieved in our experiments was always great enough to ensure that changes in agonist potency did not simply reflect low receptor expression.
In our previous three-dimensional model of hMC1R two major binding pockets were proposed for NDP-MSH. The first was a predominantly ionic binding pocket composed of receptor residues in TM2, TM3, and TM7 ) interactions. Due to the relative strength of these proposed interactions the ionic component was hypothesized to predominate within this first binding pocket. The second proposed binding pocket was a hydrophobic one consisting of a series of aromatic residues (phenylalanine and tyrosine residues) spanning TM4, -5, and -6. These functionally interconnected receptor residues were proposed to participate in aromatic-aromatic interactions with residues D-Phe 7 and Trp 9 of NDP-MSH. Predominantly Ionic Receptor Binding Pocket-The logarithmic magnitude of the changes observed in these experiments in both binding affinity and potency with alanine substitution of Tables I and II for actual IC 50 and  EC 50 values,   125 I-labeled NDP-MSH was the radioligand used in these studies. , or Asp 121 strongly implicates these amino acids as critical receptor residues involved in the NDP-MSH-hMC1R ligand-receptor interaction and the interaction of the other melanocortin agonists tested. Notably, all three of these acidic amino acids are conserved in the sequence of the five MCR subtypes. Interestingly, however, the synthetic melanocortin NDP-MSH was affected to a lesser degree by alanine substitution of Glu 94 than the other agonists tested. One implication of this observation is that Glu 94 may have a less significant role in binding NDP-MSH.
NDP-MSH-hMC1R Interactions
In an attempt to examine the hypothesis that all three acidic amino acids form a cooperative network that interacts with Arg 8 of NDP-MSH we constructed more complex mutations of these presumably spatially adjacent receptor residues. We hypothesized that if the concept of a network is correct then substitution of two or three of these negatively charged receptor residues with alanine should cause a progressive loss in agonist affinity and potency. Agonist affinity and potency in the absence of all three charges would also provide a crude measure of the strength of any remaining ligand-receptor interactions. Experimentally, substitution of two or all three of these acidic residues with alanine did lead to additional loss of agonist binding affinity and potency, but the effects of the combined mutations were not synergistic. Nonetheless, these results are consistent with the hypothesis that Glu 94 , Asp 117 , and Asp 121 act collectively as counteranions for the single cationic ligand residue Arg 8 of NDP-MSH. In addition, the presence of some agonist binding even in the absence of these apparently important acidic receptor residues implies the existence of additional points of ligand attachment. This persistence of binding despite the absence of all three negatively charged receptor residues is consistent with either the presence of other interactions within a single binding pocket or the existence of a second binding pocket (such as the hydrophobic one proposed in our model).
To further examine the proposed participation of Glu 94 , Asp
117
, and Asp 121 in ionic interactions, we examined the effects of two other mutations that were not simply removal of a negative charge by alanine substitution. Initially it was somewhat surprising to us that the asparagine substitution of Asp 121 (D121N) had more marked effects than the alanine substitution (D121A). One possible explanation is that the asparagine side chain is slightly larger than alanine and displaces the ligand from its binding pocket. Alternatively, asparagine while uncharged at neutral pH is nonetheless polar and might conceivably possess a positive charge within the receptor milieu. To more directly examine the effect of a positive charge at this position we substituted aspartic acid 121 with lysine. If as our model proposes there is a direct ionic interaction between the negatively charged receptor residue Asp 121 and the positively charged ligand residue Arg 8 of NDP-MSH, introduction of a positive charge at this receptor position (as in mutant construct D121K) should further decrease agonist binding affinity and potency compared with either D121A or D121N because of the repellent effect of such a charge substitution. Indeed, mutant D121K did display a greater loss of agonist binding affinity and potency than either of those mutants. Thus, this result could be interpreted as supporting the notion of a direct ionic interaction between receptor residue 121 and the arginine of the core melanocortin sequence.
The discussion above is limited in that it only construes results in a way that is complementary with our proposed three-dimensional model of NDP-MSH binding to hMC1R. However, alternate possible interpretations exist. Foremost, it is important to note that our data do not definitely demonstrate that there is a direct interaction between acidic receptor residues Glu 94 , Asp 117 , or Asp 121 and Arg 8 of NDP-MSH. It is possible that substitution of these acidic receptor amino acids only indirectly affects agonist binding affinity and potency. For example, these three acidic receptor residues could merely be Tables I and II for actual IC 50 and EC 50 values, 125 I-labeled NDP-MSH was the radioligand used in these studies.
essential to a framework in which the true points of attachment lie. The difficulty in resolving the issue of direct versus indirect effects of mutagenesis is, in fact, one of the major limitations of receptor mutagenesis studies such as these. In this particular instance charge exchange experiments utilizing reciprocal ligand and receptor substitutions might help clarify the issue.
Furthermore, from these data we cannot conclude that the interaction of Glu If this interpretation of pharmacological data is correct then of the residues in this tripeptide arginine is the most likely amino acid to be involved in an ionic interaction since it is the only positively charged residue. However, the agonists used in these experiments were 12 (␥-MSH) or 13 amino acids. Therefore, other agonist residues were available to interact with Glu 94 , Asp
, and Asp 121 such as the conserved histidine of the melanocortin core sequence as hypothesized by Prusis et al. (18) .
Regardless of the caveats of the last two paragraphs the present data do very clearly demonstrate that these three acidic receptor amino acids are somehow critical to the NDP-MSH-hMC1R interaction and the interaction of the other melanocortin agonists tested with the hMC1R. Even if these acidic receptor residues are only indirectly involved in ligand binding, the results of these studies at least in part support our previous model. Frä ndberg et al. (19) have previously reported that Asp 117 alters the binding affinity of ␣-MSH and ␥-MSH but not NDP-MSH in competitive binding studies using 125 I-labeled NDP-MSH. Our data confirms the differential effect of this mutation on ␣-MSH and NDP-MSH, but is quantitatively somewhat different. In agreement with Frä ndberg et al. (19) our experiments demonstrated that this mutation has a greater effect on ␣-MSH than NDP-MSH but, unlike those data, in our experiments this mutation was observed to have an effect on NDP-MSH (8-fold decrease in IC 50 and one log decrease in EC 50 ).
If indeed Asp 117 and Asp 121 are directly involved in ligand binding one could consider these TM3 residues of hMC1R as functionally homologous counterparts to the conserved TM3 aspartic acid found in the biogenic amine receptors which is thought to serve as a counteranion to cationic ligand moieties (20) . In the case of the MCRs, aspartic acid residues Asp 121 and Asp 117 reside one and two rotations, respectively, about the TM3 ␣-helix (as counted from the canonical DRY sequence present in both these receptor types) rendering them closer to the extracellular environment. This would imply that the melanocortins are unable to penetrate as deeply into the TM portion of their receptors as can the biogenic amines into theirs. That the importance of these residues can be generalized among the MCR subtypes is suggested by our observation that mutation of residues homologous to Asp 121 within the TM3 sequences of the hMC2R, hMC3R, and hMC4R results in identical changes in binding affinity and potency. 3 Finally, it is interesting to note that the MC2R, the adrenocortical receptor which only binds the melanocortin ACTH, contains yet a third aspartic acid residue in this region (equivalent to position 118 in hMC1R).
Regarding the process of receptor activation the discordance between agonist affinity and potency (values of IC 50 one log less than EC 50 ) that is observed with the double (D117A/D121A) and triple (E94A/D117A/D121A) mutants as well as the mutant D121K may be mechanistically significant. This discordance was not observed with other mutants where almost exact parity between these values is found. It would appear that despite the ability of these three mutant receptors to bind the agonist Tables I and II for actual IC 50 and  EC 50 values,   125 I-labeled NDP-MSH was the radioligand used in these studies.
NDP-MSH-hMC1R Interactions
they were not appropriately activated by agonist binding. Notably a similar discordance between agonist affinity and potency was not observed for the individual alanine mutations of the same residues (mutant constructs E94A, D117A, and D121A). The presence of a discordance in the cases of the double and triple alanine mutants and its absence with single mutations suggests that more than one of these residues must be interacting with an agonist to trigger receptor activation. In the case of mutant D121K which represents alteration of only a single member of the acidic triad (Glu 94 , Asp
117
, and Asp 121 ) the discordance between IC 50 and EC 50 values may be due to charge interference which hampers ligand binding.
In terms of activation it is also notable that a naturally occurring mouse MC1R variant E92K (which is analogous to Glu 94 of the human receptor) is the genotypic basis for the sombre E so-3J mutation (21) . This variation of the mouse MC1R results in a constitutively active receptor that responds poorly to ␣-MSH and phenotypically results in dark coat coloration. Interestingly, activation of the mouse receptor has been reported to be confined to lysine substitution of Glu 92 (22) . In our experiments we did not construct a E94K mutant to see if this substitution resulted in constitutive activation of the human receptor. However, since Asp 121 is proposed in our model to be spatially adjacent to Glu 94 we did examine the D121L mutation for constitutive activity. After carefully controlling for the level of receptor expression we compared the basal (unstimulated) cAMP production of the wild-type hMC1R and mutant D121K and found no increased cAMP production by the latter mutant.
From the perspective of agonist structure it is interesting that mutations of Glu 94 , Asp
, and Asp 121 consistently perturb MT-II affinity and potency more than NDP-MSH. As previously mentioned MT-II has slightly greater affinity and potency than NDP-MSH at the wild-type MC1R (Fig. 3) . A possible explanation for this finding is that the cyclic structure of MT-II makes it a more constrained molecule that is less able to compensate for any single receptor mutation. In contrast, the more flexible nature of NDP-MSH might allow it to more easily compensate for any one mutation by binding to alternative sites within the receptor. The additional site(s) which stabilizes NDP-MSH relative to the other agonists in the absence of Glu 94 was not identified in the present studies.
In our original model we proposed that Asn 281 in TM7 participated in the predominantly hydrophilic binding region (8) . In that model, this residue was proposed to interact differently with MT-II versus NDP-MSH. For MT-II the specific interaction consisted of an amino-aromatic interaction between Asn 281 and ligand residue Trp 9 (8, 23) . In the case of NDP-MSH the proposed interaction was only an indirect one via an extensive hydrophilic hydrogen bonding network (8, 24) . Experimentally, however, we could not detect any change in the binding affinity or potency of NDP-MSH at the mutation N281A. Nonetheless, the 68-fold difference in MT-II binding versus wild-type receptor does appear to support our proposal that this residue can participate in ligand binding by possessing different roles depending on the ligand tested. Surprisingly, replacement of Asn 281 in TM7 by Ala completely abolished ␥-MSH binding and activation while having no affect on the other agonists. As mentioned earlier, the amino acid sequence of ␥-MSH is unlike the other melanocortin peptides (Fig. 1) . The sequence of ␥-MSH differs in that the carboxyl-terminal glycine is replaced by aspartic acid and glutamic acid at position two is replaced by glycine. Very probably this profound change in ␥-MSH binding and potency is rooted in this sequence variation. The exact manner by which this relatively conservative single receptor amino acid substitution (Asn 3 Ala) effects ␥-MSH is purely speculative, but one possibility is that the interaction of ␥-MSH ) on NDP-MSH binding affinity and potency might be interpreted as casting doubt on this aspect of our model. However, in our previously proposed model the hydrophobic residues in TM4, -5, and -6 acted in concert to form a hydrophobic binding pocket. Therefore, we hypothesized that the lack of effect of single aromatic mutations within TM4 and TM5 on NDP-MSH binding affinity and potency might possibly be due to the weak nature of the forces involved in individual hydrophobic ligand-receptor interactions. Loss of a single aromatic receptor residue as a result of mutagenesis might be easily compensated by a network of aromatic-aromatic interactions (as proposed in our model) and not cause any observable effects on ligand binding or receptor activation. Therefore, to investigate our model further we created complex mutants with multiple alanine substitutions of TM4, TM5, and TM6 aromatic residues. Of note, in regards to our model, aromatic residues homologous to hMC1R Phe 196 and Phe 257 are present in all MCR subtypes and residues homologous to Phe 179 , Tyr 182 , and Phe 258 are conserved in all MCR subtypes except MC2R. This evolutionary conservation suggests the possibility that these residues have some type of functional importance (i.e. possibly in ligand binding).
The results of several of the paired aromatic mutations appear consistent with our hypothesis that it is necessary to remove more than one aromatic receptor side chain to detect the presence of aromatic-aromatic interactions otherwise undetectable with single mutations. Most notably the paired mutation of aromatic residues in TM4 and TM5, mutants Y179A/ F196A and F182A/F196A, uncovered effects essentially absent in the case of NDP-MSH with single mutations of the same residues. Pairing of aromatic mutations also augmented the modest impact that individual mutation of these same residues caused in the cases of the other agonists. This augmentation further endorses the existence of the aromatic-aromatic interactions as postulated in our model. In the case of NDP-MSH the combination of mutations F257A/F258A in TM6 resulted in augmented loss of binding affinity and potency compared with F257A alone. The lack of effect on binding affinity and potency of a single aromatic to alanine substitution within a seventransmembrane G-protein-coupled receptor and the appearance of an effect after substituting two phenylalanine residues has been reported previously in the case of the neurokinin-2 receptor and one of its antagonists (25) .
The effect of aromatic mutations within TM4, -5, and -6 on ␣-MSH, ␥-MSH, and MT-II also supports the concept of a hydrophobic hMC1R binding pocket. Individual and complex aromatic mutations actually had a greater effect on the binding affinity and potency of those agonists than they did on NDP-MSH. Collectively, these data appear to indicate the presence of an hMC1R hydrophobic binding pocket that is of general importance to all melanocortin peptides. Furthermore, the fact that NDP-MSH is affected less by aromatic mutations may relate to the previously observed ability of this compound to better withstand the absence of Glu 94 (possibly secondary to an additional as yet unidentified point(s) of attachment unique to NDP-MSH).
Finally ) from the present experiments we cannot conclude that the interactions of the aromatic receptor residues is with D-Phe 7 and Trp 9 of NDP-MSH (or equivalent residues in the other melanocortins) since the size of the agonists tested exceeds the size of the tripeptide used to develop the model. Nonetheless, these are plausible amino acids to be involved in such hydrophobic interactions.
Other Observations-The differential effect of the mutation H260A on the binding affinity of NDP-MSH and ␣-MSH has previously been described (19) . As in those previous experiments mutation of this histidine residue, which is conserved among the MCRs, affected the binding affinity of ␣-MSH but had no effect on NDP-MSH. Our experiments also demonstrate that this mutation does not affect the binding or potency of MT-II.
One of the major themes that arises from this work is that the four agonists examined do not bind to exactly the same receptor residues. Nowhere is this more evident than with ␥-MSH. Mutation of multiple charged and aromatic receptor residues dramatically affected both binding affinity and potency of ␥-MSH while having much more modest or no effects at all on the other three ligands. Perhaps these results should not be surprising since ␥-MSH is the least potent of the agonists at the wild-type hMC1R. In contrast to hMC1R, ␥-MSH is equipotent to ␣-MSH and the other naturally occurring melanocortins at hMC3R (26) . One would, therefore, expect differences to exist between the ␥-MSH binding pocket of hMC1R and hMC3R. Other examples of how mutations differentially affect the agonists include E94A and H260A. Both of these mutations have a much more marked effect on ␣-MSH and comparatively little effect on NDP-MSH or MT-II. In addition, careful study of Tables I and II reveal numerous other examples of instances in which differences exist between the agonists at the different mutations. On a positive note, the observation that a particular mutation can affect the binding affinity and potency of one ligand and not affect another can be viewed as supportive of the interpretations we have made. It suggests that a particular mutation has truly identified a receptor residue directly involved in ligand binding rather than simply singling-out a residue whose mutation only indirectly affects that process, i.e. a residue whose mutation affects binding by changing receptor structure.
Although there may be implications to our use of 125 I-labeled NDP-MSH as the radioligand to examine the binding of ␣-MSH, ␥-MSH, and MT-II, this represents a difficult dilemma since no radioligands have been described for these three melanocortin agonists. However, a very cogent argument against the observed changes in binding affinity of ␣-MSH, ␥-MSH, and MT-II being solely a result of our using the radioligand 125 I-labeled NDP-MSH to determine their IC 50 values is the fact that very similar alterations occurred in EC 50 for these agonists.
Conclusions-The present data can be interpreted as at least partially supporting our previously proposed three-dimensional model of NDP-MSH binding to hMC1R. The portion of that ligand-receptor model that is most strongly supported by the present data is the participation of negatively charged TM2 and TM3 receptor residues in an ionic ligand binding pocket. The observations that Phe 175 , Phe 196 , Phe 257 , and more complex aromatic mutations have effects on agonist affinity and potency also indicates that hydrophobic interactions play a role in the ligand-receptor interaction between melanocortins and hMC1R. However, the extent of the aromatic network in TM4, -5, and -6 suggested by our model is incompletely defined by the present studies since complex mutations of more than two aromatic residues proposed to encircle D-Phe 7 of NDP-MSH were not constructed. Our results also indicate that of the two proposed binding pockets (predominantly hydrophilic and hydrophobic) that the ionic one is of greater importance to the ligand-receptor interaction. This conclusion is based upon two observations. First, compared with the mutations within the predominantly ionic binding pocket (mutation of acidic residues in TM2 and TM3) mutations within the hydrophobic binding pocket (aromatic to alanine mutations in TM4, -5, and -6) caused comparatively small changes in agonist binding affinity and potency. Second, only modest residual agonist binding and receptor activation were displayed by mutants that lack either two or all three of the acidic residues in TM2 and TM3. It should be noted that we did not construct a mutant that disrupted both ionic interactions and hydrophobic interactions demonstrated to affect NDP-MSH binding and potency (i.e. a single mutant with substituted amino acids E94A/D117A/ D121A plus F175A/F179A/Y182A/F196A). Indeed, perhaps a single mutant which encompasses this array of substitutions would be a reasonable place to begin our further examination of the interaction of NDP-MSH with the hMC1R to determine what additional receptor residues, if any, are utilized by this ligand.
To a substantial extent it appears that the findings obtained from our mutagenesis experiments which were directed at defining the topography of the macromolecule hMC1R as it relates to NDP-MSH can be generalized in part to the three other agonists tested. However, as noted, differences clearly exist between the agonists. Whether or not portions of the receptor other than the transmembrane domains are involved in ligand binding as suggested by Chhajlani et al. (10) was not examined since these regions were not a part of our model. Nonetheless, these studies provide the first systematic examination of a rationally constructed three dimensional model of the hMC1R. 
NDP-MSH-hMC1R Interactions
results of the present experiments. His 260 and Asn 281 have been included as points of reference. While mutation of these residues do not alter the binding of NDP-MSH, they do alter the binding affinity and potency of the naturally occurring melanocortins ␣-MSH and ␥-MSH. Studies such as the one presented here require iterative optimization and further refinement of this latest model is indicated. Finally, these results should prove useful for site-directed mutagenesis of the other MCR subtypes.
